calcimedica inc glp-1 receptor agonists weight management diabetes treatments How Did Medications Become Loss Meds? Beyond Journal Club on SURMOUNT-1 Trial – Core IM Podcast Start Low, Go Slow with

Description

Wegovy contains the same semaglutide as Ozempic but at higher doses approved specifically for weight management

doi:10.3945/ajcn.116.135673

Last reviewed: June 15, 2026 Last updated: June 15, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations

doi: 10.1016/j.ygcen.2017.12.007 154 ZengXXieYJLiuYTLongSLMoZC

Abstract This review provides a comprehensive examination of the clinical pharmacological mechanisms and broad therapeutic applications of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual receptor agonists targeting both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors